Cargando…
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clini...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923655/ https://www.ncbi.nlm.nih.gov/pubmed/36780118 http://dx.doi.org/10.1007/s10238-023-01019-y |
_version_ | 1784887762030166016 |
---|---|
author | Arvanitis, Panos Lerner, Alexis Hope Vieira, Kendra Almaghlouth, Nouf Farmakiotis, Dimitrios |
author_facet | Arvanitis, Panos Lerner, Alexis Hope Vieira, Kendra Almaghlouth, Nouf Farmakiotis, Dimitrios |
author_sort | Arvanitis, Panos |
collection | PubMed |
description | Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clinical efficacy of mAbs compared to no outpatient treatment exclusively among patients with solid tumors and hematologic malignancies, who are often excluded from clinical trials. We studied patients with cancer who had COVID-19 between 11.9.2020 and 7.21.2022 and received mAbs in an outpatient setting. We compared hospitalization and mortality rates to those of patients with cancer concurrently diagnosed with COVID-19, who were eligible for mAbs, but did not receive any outpatient treatment. 63 patients received mAbs and 89 no outpatient treatment. Administration of mAbs was associated with lower 90-day hospitalization (20.6% vs. 60.7%, p <0.001), all-cause (6.3% vs. 19.1%, p 0.025) and COVID-19-attributed (3.2% vs. 14.6%, p 0.019) mortality rates, and lower peak O(2) requirements (ordinal Odds Ratio [OR] = 0.33, 95% Confidence Intervals [CI] = 0.20–0.53). Administration of mAbs (aHR 0.21, p <0.001), age (≥ 60 years, adjusted Hazard Ratio [aHR] 1.86, p=0.033), and metastases (aHR 0.41, p 0.007) were independently associated with hospitalization. mAb treatment remained significantly associated with all-cause (aHR 0.27, p 0.019) and COVID-19-attributed (aHR 0.19, p 0.031) mortality, after adjustment for other factors. mAb administration was associated with improved clinical outcomes among vulnerable patients with cancer and COVID-19. With no mAbs approved currently for treatment against the prevalent circulating variants, the development of new mAbs should be a research priority. |
format | Online Article Text |
id | pubmed-9923655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-99236552023-02-13 Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 Arvanitis, Panos Lerner, Alexis Hope Vieira, Kendra Almaghlouth, Nouf Farmakiotis, Dimitrios Clin Exp Med Research Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clinical efficacy of mAbs compared to no outpatient treatment exclusively among patients with solid tumors and hematologic malignancies, who are often excluded from clinical trials. We studied patients with cancer who had COVID-19 between 11.9.2020 and 7.21.2022 and received mAbs in an outpatient setting. We compared hospitalization and mortality rates to those of patients with cancer concurrently diagnosed with COVID-19, who were eligible for mAbs, but did not receive any outpatient treatment. 63 patients received mAbs and 89 no outpatient treatment. Administration of mAbs was associated with lower 90-day hospitalization (20.6% vs. 60.7%, p <0.001), all-cause (6.3% vs. 19.1%, p 0.025) and COVID-19-attributed (3.2% vs. 14.6%, p 0.019) mortality rates, and lower peak O(2) requirements (ordinal Odds Ratio [OR] = 0.33, 95% Confidence Intervals [CI] = 0.20–0.53). Administration of mAbs (aHR 0.21, p <0.001), age (≥ 60 years, adjusted Hazard Ratio [aHR] 1.86, p=0.033), and metastases (aHR 0.41, p 0.007) were independently associated with hospitalization. mAb treatment remained significantly associated with all-cause (aHR 0.27, p 0.019) and COVID-19-attributed (aHR 0.19, p 0.031) mortality, after adjustment for other factors. mAb administration was associated with improved clinical outcomes among vulnerable patients with cancer and COVID-19. With no mAbs approved currently for treatment against the prevalent circulating variants, the development of new mAbs should be a research priority. Springer International Publishing 2023-02-13 /pmc/articles/PMC9923655/ /pubmed/36780118 http://dx.doi.org/10.1007/s10238-023-01019-y Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Arvanitis, Panos Lerner, Alexis Hope Vieira, Kendra Almaghlouth, Nouf Farmakiotis, Dimitrios Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title | Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title_full | Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title_fullStr | Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title_full_unstemmed | Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title_short | Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19 |
title_sort | outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and covid-19 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923655/ https://www.ncbi.nlm.nih.gov/pubmed/36780118 http://dx.doi.org/10.1007/s10238-023-01019-y |
work_keys_str_mv | AT arvanitispanos outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19 AT lerneralexishope outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19 AT vieirakendra outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19 AT almaghlouthnouf outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19 AT farmakiotisdimitrios outpatientantispikemonoclonalantibodyadministrationisassociatedwithdecreasedmorbidityandmortalityamongpatientswithcancerandcovid19 |